Chemotherapy-induced cognitive impairment (CICI), also known as "chemobrain," is a range of neurocognitive deficits experienced during and after cancer chemotherapy. It is also one of the significant factors affecting the quality of life of cancer patients. Due to patients' subjective feelings, the definition of cognitive impairment, the variety of testing scales, and the lack of pre-chemotherapy cognitive function measurements, it is difficult to determine its incidence rate. Consequently, the diagnosis and treatment of this condition are delayed. Existing studies report a high incidence of CICI, affecting 17% to 78% of survivors, and it may persist for years after chemotherapy cessation, leading to more severe progressive manifestations. Its main clinical presentations include deficits in attention, memory, reasoning, multi-tasking ability, decision-making ability, as well as learning and language impairments. These significantly affect patients' functional independence, imposing a heavy burden on families and society. Numerous studies have proposed several potential mechanisms and etiologies for CICI, including direct neurotoxicity of chemotherapeutic drugs, blood-brain barrier disruption, reduced hippocampal neurogenesis, white matter abnormalities, secondary neuroinflammatory responses, and increased oxidative stress. However, the exact underlying mechanisms remain unclear. Currently, there is no clear and effective diagnosis or treatment method for CICI. How to effectively diagnose and treat cognitive impairment caused by chemobrain remains a key focus and challenge in current research.
Previous studies indicate that in the treatment of ischemic stroke, Edaravone exerts its effects by scavenging oxygen free radicals, reducing inflammatory responses, mitigating neuronal and endothelial cell damage, and inhibiting excitatory neurotoxicity. It also inhibits neuronal lipid peroxidation and alleviates brain tissue damage and cerebral edema caused by cerebral ischemia and hypoxia. Dexborneol, as a bicyclic monoterpenoid compound, can also inhibit inflammatory responses, protect blood-brain barrier permeability, and reduce cell apoptosis. The combination of these two active ingredients can exert multiple mechanisms of action, including free radical scavenging, anti-inflammation, and blood-brain barrier protection, significantly reducing neuronal damage caused by acute ischemic stroke and exerting neuroprotective effects. Clinically, it effectively reduces infarct volume and improves neurological function.
The aforementioned pathogenesis of CICI precisely involves increased neuroinflammation and oxidative stress, as well as damage to the blood-brain barrier. Furthermore, the sublingual tablet dosage form offers advantages in convenience compared to injections. Based on this, we hypothesize that Edaravone Borneol sublingual tablets may also have considerable efficacy in treating chemotherapy-related cognitive impairment.
This study addresses a clinical cross-disciplinary event in neurology and oncology. It aims to evaluate the efficacy of Edaravone Dexborneol sublingual tablets for CICI and conduct preliminary exploration of early diagnostic biomarkers for CICI by collecting clinical patient imaging data, blood samples, and neuropsychological scale results. This will ultimately help optimize chemotherapy regimens to the greatest extent.

开始日期2026-03-02

申办/合作机构

中国医科大学附属第一医院

ChiCTR2600117665

/ Not yet recruiting临床4期IIT

Effect of Early Emergency Department Administration of Sublingual Edaravone Dexborneol on Neurological Function Improvement in Acute Ischemic Stroke Patients Undergoing Reperfusion Therapy: the EARLY-AID trial

开始日期2026-02-01

申办/合作机构-

NCT06674460

/ Recruiting临床3期IIT

Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease: A Randomized, Double-Blind, Placebo-Controlled Study

This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Edaravone Dexborneol Sublingual Tablets in patients with acute ischemic stroke due to small vessel disease (TASTE-SVD).
The study will enroll approximately 600 participants aged 30 to 80 years who have experienced a recent small subcortical infarct (RSSI) confirmed by MRI. Participants will be randomized in a 1:1 ratio into either the Edaravone Dexborneol Sublingual Tablets group or the placebo group, with a 24-week treatment period followed by a 28-week follow-up.
The primary endpoint is a hierarchical composite endpoint at week 24, including all-cause mortality, modified Rankin Scale (mRS) score ≥2, recurrent stroke, changes in MoCA score, and changes in VaDAS-Cog score.
Secondary endpoints include additional functional and cognitive assessments at 24 and 52 weeks, as well as MRI markers of white matter hyperintensities, new infarctions, microbleeds, and brain atrophy. Safety assessments will include adverse events (AEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs).
The study aims to determine whether Edaravone Dexborneol Sublingual Tablets improve functional outcomes and cognitive performance in patients with small vessel disease-related stroke.

开始日期2025-08-01

申办/合作机构

北京协和医院

100 项与依达拉奉右莰醇相关的临床结果

登录后查看更多信息

100 项与依达拉奉右莰醇相关的转化医学

登录后查看更多信息

100 项与依达拉奉右莰醇相关的专利（医药）

登录后查看更多信息

项与依达拉奉右莰醇相关的文献（医药）

2026-12-31·JOURNAL OF INVESTIGATIVE SURGERY

The Effect of Edaravone Dexborneol Treatment After Intracranial Vascular Intervention on Inflammatory Factors and Oxidative Stress Level in Elderly Patients with Acute Ischemic Cerebrovascular Disease

Article

作者: Wang, Zezhao ; Dai, Xiaoyan ; Zhang, Liyuan ; Yu, Xueji ; Wang, Xi ; Qiu, Tao ; Tang, Jie

OBJECTIVE:

We aimed to explore the effects of applying edaravone dexborneol after intracranial vascular intervention on the levels of neuron-specific enolase (NSE), homocysteine (Hcy) and neurological function in elderly patients with acute ischemic cerebrovascular disease (AICVD).

METHODS:

The control group and study group were established. Serum levels of NSE, Hcy, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), and superoxide dismutase (SOD) activity were measured. Neurological function and hemorheological indices [plasma viscosity (PV), high-shear viscosity (HSV), low-shear viscosity (LSV)] were assessed. Adverse reactions and 6-month adverse outcomes were recorded.

RESULTS:

At 14 days postoperatively, the study group exhibited lower NSE, Hcy, IL-6, TNF-α, and MDA levels and higher SOD activity than the control group (all p < 0.05). NIHSS scores, PV, HSV, and LSV decreased in both groups at 7 and 14 days postoperatively (p < 0.05), with greater improvements in the study group (p < 0.05). The study group had a lower incidence of adverse outcomes (4.00% vs. 13.33%, p < 0.05).

CONCLUSION:

Edaravone dexborneol after intracranial vascular intervention significantly reduces NSE and Hcy levels, mitigates inflammation and oxidative stress, improves neurological function and hemorheology, and lowers adverse outcome rates in elderly AICVD patients without increasing adverse reactions.

2026-05-01·PHYTOMEDICINE

An integrated approach elucidates Xiongzhi Tongluo formula against ischemic stroke

Article

作者: Chang, Ze ; Liu, Longtao ; Wei, Jingjing ; Miao, Lina ; Niu, Qikai ; Liang, Xiao ; Liu, Yue ; Zhang, Yunling ; Liu, Hongxi ; Qu, Hua ; Zhao, Di ; Cao, Weiyi ; Wang, Liuding ; Zhang, Yunfan ; Zhang, Qi ; Yao, Mingjiang

BACKGROUND:

Ischemic stroke (IS) remains a critical challenge in stroke management. Xiongzhi Tongluo formula (XZTLF), a traditional Chinese herbal prescription, has shown potential in treating ischemic stroke, yet its mechanisms remain elusive.

METHODS:

This integrated study combined clinical and in vivo approaches to investigate XZTLF. We first employed network node similarity algorithms, ultra-high performance liquid chromatography quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF/MS)-based phytochemical profiling, and network pharmacology to identify potential molecular targets for ischemic stroke (IS) intervention. The predicted hub genes were then validated through molecular docking and a multicenter randomized controlled trial in patients with acute IS. For in vivo validation, a middle cerebral artery occlusion (MCAO) rat model was used. Rats were treated with XZTLF via oral gavage at doses of 2.97 or 11.88 g/kg/day for 7 days, using edaravone dexborneol (10 mg/kg, i.p.) as a positive control. Key targets and mechanisms of action were further assessed through biochemical and histological analyses of rat brain tissue.

RESULTS:

XZTLF demonstrated significantly closer network-based proximity to IS targets compared to control prescriptions. Chemical systematic pharmacology analysis identified 173 bioactive constituents in XZTLF. Network pharmacology screening revealed eight core targets (NFKB1, BCL2L1, MAPK1, STAT1, CDKN2A, AR, RAF1, and MMP2), which were subsequently validated in IS patients through ELISA quantification. In MCAO rat models, XZTLF administration significantly reduced cerebral infarct volume and improved neurological function. Mechanistically, XZTLF attenuated neuroinflammation by downregulating pro-inflammatory mediators (including IL-6, TNF-α, and NF-κB), mitigated oxidative damage (MDA, SOD, CAT), and suppressed hyperactivation of the PI3K/AKT signaling pathway.

CONCLUSION:

XZTLF shows potential for treating IS through multimodal regulation of neuroinflammatory cascades, redox homeostasis, and autophagy pathways, based on integrated preclinical and preliminary clinical findings.

2026-03-01·Brain and Behavior

Prospective Open‐Label Safety Study of Edaravone Dexborneol in Filipino Patients With Acute Ischemic Stroke

Article

作者: Sabellano, Zenyros Faith ; Batino, Laurence Kristoffer ; Pedregosa, Bonifacio ; Navarro, Jose

ABSTRACT:

Background:

Edaravone dexborneol is a neuroprotective agent combining the free‐radical scavenging properties of edaravone and the anti‐inflammatory, blood–brain barrier–modulating effects of dexborneol. While international trials have demonstrated favorable safety and potential clinical benefit, data in Filipino patients remain lacking. This study evaluated the real‐world safety and tolerability of edaravone dexborneol among Filipino patients with acute ischemic stroke.

Methods:

This was a single‐center, open‐label, single‐arm, prospective study conducted under a compassionate‐use program. Patients aged 18–80 years with clinically confirmed acute ischemic stroke within 48 h of onset received edaravone dexborneol (30 mg edaravone + 7.5 mg dexborneol) twice daily for 14 days. Safety monitoring continued until Day 20. Treatment‐emergent adverse events (TEAEs) and serious adverse events (SAEs) were classified using the International Council for Harmonisation (ICH E2A) criteria, and causality was assessed using the World Health Organization–Uppsala Monitoring Centre (WHO–UMC) categories.

Results:

Twenty‐seven of 29 enrolled patients completed the 14‐day regimen. Mean age was 55.7 ± 12.8 years; 66.7% were male. Overall, 15 patients (55.6%) experienced at least one TEAE, most commonly headache (29.6%), which occurred on Day 0 and resolved within 0.7 ± 1.2 days. Elevated liver enzymes were observed in 25.9% for aspartate transaminase (AST) as well as for alanine aminotransferase (ALT), generally mild and self‐limited. One patient developed both moderate transaminitis and acute kidney injury, attributed to concurrent antituberculosis therapy rather than the study drug. No treatment discontinuations, life‐threatening reactions, or deaths occurred.

Conclusion:

Edaravone dexborneol demonstrated a favorable safety profile in Filipino patients with acute ischemic stroke, with adverse events (AE) predominantly mild, transient, and reversible. These real‐world findings align with international data and support their potential incorporation into acute stroke management pathways in the Philippines.

275

项与依达拉奉右莰醇相关的新闻（医药）

2026-04-05

·信狐药迅

明慧医药伊托法替布和上海海和艾普美妥司他提交上市申请|新受理（3.30-4.5）

本周药品注册受理数据，分门别类呈现，一目了然。(3.30-4.5）新药上市申请药品名称企业注册分类受理号伊托法替布软膏明慧医药(杭州)有限公司 1 CXHS2600045 艾普美妥司他片上海海和药物研究开发股份有限公司 1 CXHS2600047 艾普美妥司他片上海海和药物研究开发股份有限公司 1 CXHS2600046 司普奇拜单抗注射液成都康诺行生物医药科技有限公司 2.2 CXSS2600062 司普奇拜单抗注射液成都康诺行生物医药科技有限公司 2.2 CXSS2600061 新药临床申请药品名称企业注册分类受理号 D-0120-NA片益方生物科技(上海)股份有限公司 1 CXHL2600406 VC005凝胶江苏威凯尔医药科技股份有限公司 1 CXHL2600405 CB03-154片上海挚盟医药科技有限公司 1 CXHL2600403 ARD-489AD片科辉智药(深圳)新药研究中心有限公司 1 CXHL2600402 ARD-489AD片科辉智药(深圳)新药研究中心有限公司 1 CXHL2600401 HRS9531注射液福建盛迪医药有限公司 1 CXHL2600400 HRS9531注射液福建盛迪医药有限公司 1 CXHL2600399 HRS9531注射液福建盛迪医药有限公司 1 CXHL2600398 注射用WP1302 百明信康生物技术(浙江)股份有限公司 1 CXHL2600395 优替德隆胶囊成都华昊中天药业有限公司 2.2 CXHL2600404 DMET25001缓释片武汉龙升医药科技有限责任公司 2.2;2.4 CXHL2600397 DMET25001缓释片武汉龙升医药科技有限责任公司 2.2;2.4 CXHL2600396 猴痘mRNA疫苗江苏中慧元通生物科技股份有限公司 1.2 CXSL2600362 SK-NK注射液赛奥斯博生物科技(北京)有限公司 1 CXSL2600380 注射用DXC018 杭州多禧生物科技有限公司 1 CXSL2600375 注射用SIM0689 上海先纬医药科技有限公司 1 CXSL2600374 SAR445877注射用浓溶液赛诺菲(中国)投资有限公司 1 CXSL2600378 ATTO-1310注射液艾拓维医药(上海)有限公司 1 CXSL2600377 9MW5211注射液迈威(上海)生物科技股份有限公司 1 CXSL2600376 GT307注射液北京沙砾生物医药股份有限公司 1 CXSL2600379 注射用Efimosfermin alfa 葛兰素史克(中国)投资有限公司 1 CXSL2600372 注射用GenSci136 长春金赛药业有限责任公司 1 CXSL2600371 普那利单抗注射液天境生物药业(杭州)股份有限公司 1 CXSL2600373 GT101注射液苏州沙砾生物科技有限公司 1 CXSL2600365 LNF2401注射液(皮下注射) 山东新时代药业有限公司 1 CXSL2600370 LNF2401注射液(静脉滴注) 山东新时代药业有限公司 1 CXSL2600369 CMG2349注射液成都恩沐生物科技有限公司 1 CXSL2600368 BBT001注射液杉竹曜(北京)生物医药科技有限公司 1 CXSL2600364 ADRX-0405 上海德烽药业有限公司 1 CXSL2600358 注射用BL-M14D1 成都百利多特生物药业有限责任公司 1 CXSL2600361 IBI354 信达生物医药科技(杭州)有限公司 1 CXSL2600360 ICP-B208 北京诺诚健华医药科技有限公司 1 CXSL2600359 注射用QLF4113 齐鲁制药有限公司 1 CXSL2600363 特瑞普利单抗注射液上海君实生物医药科技股份有限公司 2.2 CXSL2600367 特瑞普利单抗注射液上海君实生物医药科技股份有限公司 2.2 CXSL2600366 仿制药申请药品名称企业注册分类受理号盐酸奥洛他定颗粒九华华源药业(桂林)有限公司 3 CYHS2600785 富马酸酮替芬口服溶液安徽远望乐桓药业有限公司 3 CYHS2600784 镥[177Lu]氧奥曲肽注射液天津恒瑞医药有限公司 3 CYHS2600762 比拉斯汀口崩片江西施美药业股份有限公司 3 CYHS2600754 依巴斯汀口服溶液江苏晨牌邦德药业有限公司 3 CYHS2600749 盐酸拉贝洛尔片重庆圣华曦药业股份有限公司 3 CYHS2600756 盐酸拉贝洛尔片重庆圣华曦药业股份有限公司 3 CYHS2600755 利格列汀二甲双胍缓释片南通联亚药业股份有限公司 3 CYHS2600745 利格列汀二甲双胍缓释片南通联亚药业股份有限公司 3 CYHS2600746 精氨酸布洛芬颗粒广州欧化药业有限公司 4 CYHS2600777 精氨酸布洛芬颗粒广州欧化药业有限公司 4 CYHS2600775 他达拉非片江苏万高药业股份有限公司 4 CYHS2600780 他达拉非片江苏万高药业股份有限公司 4 CYHS2600779 他达拉非片江苏万高药业股份有限公司 4 CYHS2600778 氯吡格雷阿司匹林片中曦(福建)药业有限公司 4 CYHS2600776 卡铂注射液辰欣药业股份有限公司 4 CYHS2600782 卡铂注射液辰欣药业股份有限公司 4 CYHS2600781 普托马尼片沈阳红旗制药有限公司 4 CYHS2600783 苯磺酸左氨氯地平片辽宁福源药业有限公司 4 CYHS2600772 褪黑素颗粒大玮(安徽)药业有限公司 4 CYHS2600771 褪黑素颗粒大玮(安徽)药业有限公司 4 CYHS2600770 马来酸非尼拉敏盐酸萘甲唑啉滴眼液浙江视方极医药科技有限公司 4 CYHS2600769 氧氟沙星滴眼液南京帝昌医药科技有限公司 4 CYHS2600768 瑞维那新吸入溶液津药和平(天津)制药有限公司 4 CYHS2600767 塞来昔布胶囊迪沙药业集团有限公司 4 CYHS2600766 乙酰半胱氨酸注射液安徽新世纪药业有限公司 4 CYHS2600765 精氨酸布洛芬颗粒广州欧化药业有限公司 4 CYHS2600774 盐酸美金刚片山东方明药业集团股份有限公司 4 CYHS2600773 碳酸镧咀嚼片湖南华纳大药厂股份有限公司 4 CYHS2600761 依达拉奉右莰醇注射用浓溶液山东百诺医药股份有限公司 4 CYHS2600760 苯磺酸美洛加巴林片九华华源药业(桂林)有限公司 4 CYHS2600759 阿帕他胺片南京正大天晴制药有限公司 4 CYHS2600764 磷酸芦可替尼片湖北长江瑞益医药科技有限公司 4 CYHS2600763 孟鲁司特钠咀嚼片山东普瑞曼药业有限公司 4 CYHS2600753 孟鲁司特钠咀嚼片山东普瑞曼药业有限公司 4 CYHS2600752 盐酸依匹斯汀片山西同达药业有限公司 4 CYHS2600751 盐酸依匹斯汀片山西同达药业有限公司 4 CYHS2600750 双氯芬酸二乙胺乳胶剂贵州联盛药业有限公司 4 CYHS2600758 双氯芬酸二乙胺乳胶剂贵州联盛药业有限公司 4 CYHS2600757 注射用右兰索拉唑南京海纳制药有限公司 4 CYHS2600748 氟比洛芬钠滴眼液朗天药业(湖北)有限公司 4 CYHS2600747 瑞巴派特片浙江英格莱制药有限公司 4 CYHS2600744 糠酸莫米松乳膏江苏盈科生物制药有限公司 4 CYHS2600743 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600060 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600052 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600051 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600059 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600058 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600057 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600056 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600055 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600054 司美格鲁肽注射液成都倍特生物制药有限公司 3.3 CXSS2600053 进口申请药品名称企业注册分类受理号硫酸瑞美吉泮口崩片 Pfizer Inc. 5.1 JXHS2600034 帕博利珠单抗注射液(皮下注射) Merck Sharp & Dohme B.V. 2.2 JXSS2600031 帕博利珠单抗注射液(皮下注射) Merck Sharp & Dohme B.V. 2.2 JXSS2600030 奥妥珠单抗注射液 Roche Pharma (Schweiz) AG 2.2 JXSS2600025 注射用德曲妥珠单抗 Daiichi Sankyo Europe GmbH 2.2 JXSS2600024 帕博利珠单抗注射液(皮下注射) Merck Sharp & Dohme B.V. 3.1 JXSS2600029 帕博利珠单抗注射液(皮下注射) Merck Sharp & Dohme B.V. 3.1 JXSS2600028 帕博利珠单抗注射液(皮下注射) Merck Sharp & Dohme B.V. 3.1 JXSS2600027 帕博利珠单抗注射液(皮下注射) Merck Sharp & Dohme B.V. 3.1 JXSS2600026 Baxdrostat片 AstraZeneca AB 1 JXHL2600099 AZD8965片 AstraZeneca AB 1 JXHL2600098 AZD8965片 AstraZeneca AB 1 JXHL2600097 ASP3082注射液 Astellas Pharma Global Development, Inc. 1 JXHL2600095 硫酸瑞美吉泮口崩片 Pfizer Inc. 2.4 JXHL2600096 PF-08634404 Pfizer Inc. 1 JXSL2600089 注射用维恩妥尤单抗 Astellas Pharma Global Development, Inc. 2.2 JXSL2600091 注射用维恩妥尤单抗 Astellas Pharma Global Development, Inc. 2.2 JXSL2600090 Depemokimab注射液 GlaxoSmithKline Research & Development Limited 2.2 JXSL2600088 中药相关申请药品名称企业注册分类受理号热毒宁颗粒江苏康缘药业股份有限公司 2.1 CXZS2600018 ZYY-768颗粒扬子江药业集团江苏龙凤堂中药有限公司 1.1 CXZL2600033 椿乳凝胶株洲千金药业股份有限公司 2.3 CXZL2600034 注：绿色字体部分为潜在首仿品种；咸达数据2026年1月每月药讯已出！关注“咸达数据”，微信关键词回复 ” 年+月，如202601” 获得最新药迅！不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

疫苗申请上市信使RNA临床申请

2026-04-04

·赛柏蓝

62个谈判药品拟进大三甲

编者按：本文来自米内网，作者梧桐；赛柏蓝授权转载，编辑相宜日前，广元市第一人民医院发布公告，拟对药品进行询价，响应文件递交截止时间及采购开始时间为4月9日上午09:30。62个药品在列（以包号计），化学药、生物药均有涉及，既有醋酸戈舍瑞林缓释植入剂、丁苯酞氯化钠注射液等超40亿大品种，也有托莱西单抗注射液、富马酸奥赛利定注射液等多个2025年销售额增速达三位数及以上的潜力品种。 62个药品均已纳入国家医保乙类目录，且大部分为近年来新获批上市的创新药，集中在消化系统及代谢药、神经系统药物、心脑血管系统药物等治疗大类。此次询价的药品以独家品种（含独家剂型）为主，占比超过85%。国内企业中，恒瑞医药以7个独家品种领跑，包括注射用瑞卡西单抗、全氟己基辛烷滴眼液、富马酸泰吉利定注射液等多个创新药；石药集团以3个品种紧接在后，海思科医药、先声药业均有2个品种在列。跨国药企中，阿斯利康、诺和诺德、勃林格殷格翰、诺华等各有2个及以上的独家品种在列，其中诺和诺德的产品均为糖尿病用药，勃林格殷格翰的产品均为溶栓药。谈判药品批量询价项目来源：广元市第一人民医院，米内网数据库数据显示，2025年中国公立医疗机构终端司美格鲁肽注射液销售额超过50亿元，醋酸戈舍瑞林缓释植入剂、丁苯酞氯化钠注射液销售额均超过40亿元，甲磺酸奥希替尼片超30亿元，依达拉奉右莰醇注射用浓溶液超20亿元等。醋酸戈舍瑞林缓释植入剂是一款可在体内逐渐进行生物降解的多聚缓释植入剂，长期使用可抑制脑垂体促性腺激素的分泌，适用于前列腺癌、乳腺癌、子宫内膜异位症等的治疗。该药目前仅阿斯利康拥有生产批文，近年来在中国公立医疗机构终端持续放量，2025年其销售额超过44亿元，同比增长9.56%。近年来中国公立医疗机构终端醋酸戈舍瑞林缓释植入剂销售情况（单位：万元）此外，2025年氢溴酸替格列汀片、托莱西单抗注射液、重组人凝血酶的销售额同比增长均超1000%；盐酸伊立替康脂质体注射液(Ⅱ)、注射用戈舍瑞林微球、注射用盐酸曲拉西利、富马酸奥赛利定注射液、西格列他钠片等20个品种均有三位数的增长。西格列他钠片是成都微芯药业开发的一款PPAR全激动剂，适用于改善成人2型糖尿病患者的血糖控制。该药最早于2021年10月获批上市，2024年在中国公立医疗机构终端的销售额突破1亿元，同比增长321.29%；2025年超过3亿元，同比增长145.73%。近年来中国公立医疗机构终端西格列他钠片销售情况（单位：万元） END 内容沟通：Xinmeitizhongxin- 商务合作：13810647732

2026-04-03

·米内网

【市场】62个谈判药品拟进院，独家品种霸屏

精彩内容日前，广元市第一人民医院发布公告，拟对药品进行询价，响应文件递交截止时间及采购开始时间为4月9日上午09:30。62个药品在列（以包号计），化学药、生物药均有涉及，既有醋酸戈舍瑞林缓释植入剂、丁苯酞氯化钠注射液等超40亿大品种，亦有托莱西单抗注射液、富马酸奥赛利定注射液等多个2025年销售额增速达三位数及以上的潜力品种。 62个药品均已纳入国家医保乙类目录，且大部分为近年来新获批上市的创新药，集中在消化系统及代谢药、神经系统药物、心脑血管系统药物等治疗大类。此次询价的药品以独家品种（含独家剂型）为主，占比超过85%。国内企业中，恒瑞医药以7个独家品种领跑，包括注射用瑞卡西单抗、全氟己基辛烷滴眼液、富马酸泰吉利定注射液等多个创新药；石药集团以3个品种紧接在后，海思科医药、先声药业均有2个品种在列。跨国药企中，阿斯利康、诺和诺德、勃林格殷格翰、诺华等各有2个及以上的独家品种在列，其中诺和诺德的产品均为糖尿病用药，勃林格殷格翰的产品均为溶栓药。谈判药品批量询价项目来源：广元市第一人民医院，米内网数据库米内网数据显示，2025年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端司美格鲁肽注射液销售额超过50亿元，醋酸戈舍瑞林缓释植入剂、丁苯酞氯化钠注射液销售额均超过40亿元，甲磺酸奥希替尼片超30亿元，依达拉奉右莰醇注射用浓溶液超20亿元等。醋酸戈舍瑞林缓释植入剂是一款可在体内逐渐进行生物降解的多聚缓释植入剂，长期使用可抑制脑垂体促性腺激素的分泌，适用于前列腺癌、乳腺癌、子宫内膜异位症等的治疗。该药目前仅阿斯利康拥有生产批文，近年来在中国公立医疗机构终端持续放量，2025年其销售额超过44亿元，同比增长9.56%。近年来中国公立医疗机构终端醋酸戈舍瑞林缓释植入剂销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局此外，2025年氢溴酸替格列汀片、托莱西单抗注射液、重组人凝血酶的销售额同比增长均超1000%；盐酸伊立替康脂质体注射液(Ⅱ)、注射用戈舍瑞林微球、注射用盐酸曲拉西利、富马酸奥赛利定注射液、西格列他钠片等20个品种均有三位数的增长。西格列他钠片是成都微芯药业开发的一款PPAR全激动剂，适用于改善成人2型糖尿病患者的血糖控制。该药最早于2021年10月获批上市，2024年在中国公立医疗机构终端的销售额突破1亿元，同比增长321.29%；2025年超过3亿元，同比增长145.73%。近年来中国公立医疗机构终端西格列他钠片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至4月3日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com 稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

100 项与依达拉奉右莰醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	N07XX14	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性缺血性卒中	中国	先声药业有限公司	2024-12-01
脑梗塞	中国	先声药业有限公司	2020-07-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
雄激素不敏感综合征	临床3期	-	先聲藥業集團有限公司	2023-12-28
认知功能障碍	临床2期	中国	先聲藥業集團有限公司	2024-04-08
脑出血	临床2期	-	江苏先声药业有限公司	2021-03-01
高血压脑病	临床2期	-	江苏先声药业有限公司	2021-03-01
颅内出血	临床1期	美国	烟台益诺依宁企业咨询有限公司	2018-10-25
肌萎缩侧索硬化	临床申请	美国	南京宁丹新药技术股份有限公司	-
认知障碍	临床申请	美国	南京宁丹新药技术股份有限公司	-
阿尔茨海默症	临床前	中国	南京大学	2025-06-21
神经炎症	临床前	中国	长江大学	2024-03-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04667637 (Pubmed \| Nat Commun)	临床2期	缺血性卒中	-	Edaravone dexborneol	積憲蓋醖齋鬱繭範淵膚(製願繭鏇憲範鏇壓願顧): unadjusted odds ratio = 1.37 (95% CI, 0.76 ~ 2.44), P-Value = 0.29	不佳	2025-03-10
				Placebo
ISC2025	N/A	急性缺血性卒中	-	Edaravone Dexborneol	願網蓋醖醖壓顧網鬱製(艱憲艱淵鬱鬱網鬱艱衊) = 構繭鹽簾蓋觸夢繭鬱鏇鬱齋窪壓艱餘壓網觸製 (築網艱醖餘觸廠壓窪鏇 )	积极	2025-01-30
				No Edaravone Dexborneol	願網蓋醖醖壓顧網鬱製(艱憲艱淵鬱鬱網鬱艱衊) = 鑰遞製願選憲艱築願鬱鬱齋窪壓艱餘壓網觸製 (築網艱醖餘觸廠壓窪鏇 )
ISC2025	N/A	急性缺血性卒中	4,684	Edaravone Dexborneol	製餘積鏇廠鹹壓願窪製(範壓顧齋餘蓋願蓋構淵): adjusted common odds ratio = 1.02 (95% CI, 1.02 ~ 1.64), P-Value = 1.30	积极	2025-01-30
				No Edaravone Dexborneol
NCT04950920 (TASTE-SL, Literature) 人工标引	临床3期	急性缺血性卒中	914	Edaravone Dexborneol	餘夢衊窪遞壓繭餘觸觸(鬱憲襯窪繭鏇鑰憲壓顧) = 選蓋鑰製鹽觸餘鏇遞遞獵鏇壓窪衊構網糧衊襯 (鹹艱憲鏇淵鹹膚壓鏇鹽 ) 更多	积极	2024-02-19
				Placebo	餘夢衊窪遞壓繭餘觸觸(鬱憲襯窪繭鏇鑰憲壓顧) = 夢選廠構膚襯膚餘壓齋獵鏇壓窪衊構網糧衊襯 (鹹艱憲鏇淵鹹膚壓鏇鹽 ) 更多
CTR20210233 (Corporate Publications) 人工标引	临床3期	急性缺血性卒中	-	先必新	鹹鬱鬱簾襯範獵鑰遞築(蓋壓範願淵積願憲鹹鑰) = 初步分析显示，相对于安慰剂，先必新舌下片显著改善AIS患者治疗后神经功能恢复及独立生活能力，达到预期疗效终点鏇鏇積憲鏇淵齋顧積壓 (獵獵範淵範壓衊鬱獵衊 ) 达到	积极	2022-12-01
				Placebo
NEWS 人工标引	N/A	急性缺血性卒中	94	先必新	網鏇襯範獵糧淵窪壓廠(齋襯壓鹽艱獵鹹醖衊襯) = 選膚簾鑰範選糧願壓膚醖窪觸艱鏇窪顧範衊鹽 (廠觸製鹽蓋廠壓鏇築築, 4.11) 更多	积极	2022-05-06
				先必新+Alteplase	網鏇襯範獵糧淵窪壓廠(齋襯壓鹽艱獵鹹醖衊襯) = 壓顧窪齋鹽觸憲選範範醖窪觸艱鏇窪顧範衊鹽 (廠觸製鹽蓋廠壓鏇築築, 2.15) 更多
NCT02430350 (Cochrane Database Syst Rev \| Pubmed \| Stroke) 人工标引	临床3期	急性缺血性卒中	1,165	Edaravone+Dexborneol	艱選鏇糧鏇淵鏇構醖餘(廠積獵範糧醖範醖選築) = 繭醖積範獵築齋糧鹹製糧願顧觸遞膚鹹積鏇願 (衊夢憲襯艱夢獵積壓製 ) 更多	优效	2021-03-01
				Edaravone	艱選鏇糧鏇淵鏇構醖餘(廠積獵範糧醖範醖選築) = 廠鹽鑰鏇製壓齋艱網醖糧願顧觸遞膚鹹積鏇願 (衊夢憲襯艱夢獵積壓製 )
NCT01929096 (Pubmed) 人工标引	临床2期	急性缺血性卒中	385	Edaravone Dexborneol	構蓋觸餘蓋願憲網窪膚(淵艱網鏇顧廠簾鹹製觸): P-Value = 0.6799 更多	积极	2019-04-22
				Edaravone